Nature's Sunshine Cuts FY26 Guidance After Q3 Sales Fall 9% and EPS Halves to $0.11
NATR is trading near its 52-week low of $11.92 (9.4% below the low).
Summary
Q3 sales fell 9% to $116.6 million and EPS came in at $0.11 versus $0.30 a year ago, prompting a cut to full-year sales and Adjusted EBITDA guidance. Cash of $89.4 million and no debt limit near-term risk, but China weakness and a 64.8% tax rate drove the miss.
Key Events · Earnings and Guidance · NATR
-
Q3 Sales Fall 9% to $116.6M
Net sales came in at $116.6 million versus $128.3 million a year earlier, a 9.1% decline (7.2% in constant currency).
-
EPS Halves to $0.11
GAAP net income attributable to common shareholders fell to $1.9 million, or $0.11 per diluted share, from $5.3 million ($0.30). Adjusted EBITDA dropped to $11.1 million from $15.2 million.
-
Full-Year Guidance Cut
FY26 net sales are now guided to $460-$470 million (from $490-$500 million) and Adjusted EBITDA to $44-$48 million (from $48-$52 million).
-
China and Asia Weakness
Asia net sales fell 14.9% to $55.1 million, while China dropped 48.8% after operational disruptions to the consultant leadership base. The effective tax rate rose to 64.8% from 42.8%.
Analysis · NATR · Life Sciences
The full-year outlook is now lower: sales are guided to $460-$470 million from $490-$500 million, and Adjusted EBITDA to $44-$48 million from $48-$52 million. Q3 itself was weak, with net income down to $1.9 million ($0.11 per diluted share) from $5.3 million ($0.30), China sales off 48.8%, and the tax rate jumping to 64.8%. The balance sheet offers some cushion — $89.4 million of cash and zero debt — but the earnings trajectory is deteriorating and the stock is already near its 52-week low.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.6% of the 1192 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.37%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NATR was trading at $10.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $225.9M. The 52-week trading range was $11.92 to $28.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.